ZVSA
ZyVersa Therapeutics, Inc. (ZVSA) Economic Moat Analysis (2026)
No material changes this month.
Intangible Assets
ZVSA does not show evidence of durable brand, patent, or regulatory exclusivity in the provided filings-based inputs, so it lacks the kind of protected intangible asset base that would support peer-leading pricing power.
Negative TTM ROIC and ROCE indicate the company is not converting any claimed intangible advantage into economic returns, which is materially weaker than peers with proven monetization of IP or brand.
The absence of 5-year profitability and margin history in the supplied metrics suggests no demonstrated long-lived asset advantage, whereas stronger peers typically show repeatable margin support from protected assets.
Without visible customer-recognized differentiation or exclusive rights, any intangible advantage appears replicable and therefore does not materially improve retention versus peers.
Switching Costs
The provided metrics do not indicate embedded workflows, contractual lock-in, or integration depth, so customers appear able to switch without meaningful economic penalty.
Negative ROIC and ROCE imply the business is not retaining value through recurring, sticky relationships, which is far below peers with high renewal or usage inertia.
No evidence of proprietary data, regulated process dependence, or mission-critical adoption is provided, so switching costs do not appear to protect margins over a 5–10 year horizon.
Compared with peers that benefit from software, platform, or service integration lock-in, ZVSA shows no clear structural retention advantage.
Network Effects
The supplied information does not show a user, data, or ecosystem flywheel, so there is no evidence that each additional customer makes the product more valuable for others.
Negative returns on capital suggest the company is not yet benefiting from scale-driven adoption dynamics that would typically accompany network effects.
No peer-dependent platform role or industry-standard position is indicated, which means competitors are unlikely to be disadvantaged by ZVSA’s presence.
Relative to peers with measurable two-sided or data-network advantages, ZVSA appears to have no durable network-based moat.
Cost Advantage
TTM ROIC of -16.5% and ROCE of -15.1% indicate the company is not operating with a cost structure that converts into superior economic spread versus peers.
The zero asset turnover reading in the supplied metrics does not support evidence of efficient asset use, which weakens any claim to a structural cost advantage.
No scale purchasing, manufacturing, or distribution advantage is evidenced in the provided data, so cost leadership is not visible as a moat driver.
Compared with peers that can underprice while preserving margins, ZVSA shows no sign of a durable cost edge that would pressure competitors.
Efficient Scale
The available metrics do not indicate a concentrated market position or regulated bottleneck, so the company does not appear to operate in a naturally limited market structure.
Negative capital returns suggest the business is not extracting monopoly-like economics from a small addressable niche, which is typically required for efficient-scale protection.
No evidence is provided that the market can support only one or a few profitable incumbents, so peer entry does not appear structurally constrained.
Relative to peers with infrastructure, utility, or niche-regulated advantages, ZVSA shows no sign of efficient-scale insulation from competition.
Overall Score
ZVSA shows no observable durable moat in the provided data, as negative capital returns and missing evidence of protected intangibles, switching costs, network effects, cost advantage, or efficient scale indicate weak peer-relative pricing power and retention.
Sources
- Company filings (10-K, 10-Q, investor presentations)
- Financial and market data providers
- Public news and industry information
🔒 Go Beyond This Framework
This is one of 10 institutional-grade frameworks Invetso runs on ZyVersa Therapeutics, Inc.. Unlock the complete analysis — SWOT, Economic Moat, Porter’s Five Forces, Management, PESTLE and the Invetso Quality Score.
